Introduction
The renin-angiotensin system has a well-established role in cardiovascular physiology and the pathogenesis of cardiovascular and renal disease. Inhibition of angiotensin (Ang) II generation by angiotensin-converting enzyme (ACE) inhibitors and of Ang II action by angiotensin receptor blockers (ARB) has proven benefits in the prevention of cardiovascular and renal disease and, more recently, renin inhibition has gained a role in the treatment of hypertension. In addition to renin and ACE, many other enzymes, such as chymase, either cleave angiotensinogen to produce Ang I or Ang II or convert Ang I to Ang II in vitro 1 but there is uncertainty about their role in physiology and in disease. This review will briefly summarise evidence for the contribution of such enzymes to Ang II generation in vivo.
The role of renin
The classical approach to assessing the role of renin in Ang II formation was to perform nephrectomy to remove circulating renin. Chronically anephric humans have plasma Ang I and Ang II levels corresponding to approximately 6% of the levels in normal subjects, 2 but these levels are not necessarily evidence for non-renin (and non-prorenin) Ang formation. Although the kidney is the only known source of circulating renin, the precursor prorenin is made in many different tissues 3 and plasma prorenin levels are normally about five-fold higher than renin levels. 3 Anephric subjects have plasma levels of renin activity that are approximately 7% of the levels in normal individuals, whereas plasma prorenin levels are about 66% of normal, 2 and the low level of renin activity in anephric subjects can by accounted for by the intrinsic activity of prorenin, corresponding to 2% of the total potential activity of plasma prorenin. 3 Given that anephric subjects had a two-fold elevation of plasma angiotensinogen levels, this low level of intrinsic activity of prorenin was sufficient to account for the low levels of Ang I and Ang II in anephric plasma. Whereas some animal studies show the disappearance of renin and Ang peptides from plasma and tissues, such as heart, within 30 hours after nephrectomy, 4 other studies show the persistence of near-normal levels of Ang peptides for 24 to 48 hours following acute nephrectomy because of the slow rate of clearance of renin from tissues and the marked four-to eight-fold increase in plasma angiotensinogen levels. 5 Confirmation of the dominant role of renin in Ang II formation was provided by studies of renin (and prorenin) gene knockout mice and rats, which have undetectable plasma levels of Ang I, and the effects of renin (and prorenin) deficiency in humans. [6] [7] [8] Further evidence is provided by the marked suppression of plasma Ang I and Ang II levels by renin inhibitors. [9] [10] Although serine proteases may contribute to Ang peptide formation at tissue sites of inflammation, 1 the available evidence indicates that nonrenin pathways of Ang formation are clearly unable to compensate for renin deficiency or inhibition.
The role of ACE
Ang II levels are detectable in the ACE gene knockout mouse but not in the angiotensinogen gene knockout mouse 11 thereby indicating that enzymes other than ACE may contribute to Ang II formation. However, ACE gene knockout mice, ACE deficiency in humans, and ACE inhibition in humans and animals models indicate that Ang II formation in plasma and tissues is predominantly due to ACE. 8, [12] [13] When interpreting the persistence of Ang II levels in ACE gene knockout mice and animals given ACE inhibitors, it is important to take into account the accompanying changes in renin and Ang I levels. Thus, in rats administered perindopril, although plasma Ang II levels were 30% to 40% of control levels, plasma renin levels were increased 100-fold and Ang I levels were increased 30-fold, and the 99% reduction in Ang II/Ang I ratio provided a much better indication of the role of ACE in Ang II formation than the changes in Ang II levels alone. 13 Kidney, heart, and other tissues show a similar suppression of the Ang II/Ang I ratio with ACE inhibition. [12] [13] ACE inhibition also reduces Ang II levels and the Ang II/Ang I ratio in the plasma and atria of patients receiving ACE inhibitor therapy, [14] [15] demonstrating the predominant role of ACE in Ang II formation in the human heart.
The role of chymase
The potential for chymase conversion of Ang I to Ang II is species-specific in that Ang I is a good substrate for human, dog, hamster, and mouse chymase whereas it is a poor substrate for rat chymase. [16] [17] [18] The report that chymase is the major Ang II-forming enzyme in the human heart 19 was in marked contrast to studies of genetic models of ACE expression, 12, 20 and led to a reassessment of the role of ACE in Ang II formation in the heart. However, several aspects of the chymase hypothesis appear to be inconsistent with clinical experience. The cardiac benefits of ACE inhibition are attributed in part to the suppression of cardiac Ang II levels and it is of note that chymase is not inhibited by ACE inhibitors. Thus, patients administered ACE inhibitor therapy who develop increased plasma and cardiac Ang I levels [14] [15] would be expected to have increased cardiac Ang II levels if chymase was the major pathway of Ang II formation in the heart. Yet, the opposite occurs. 14 Furthermore, the chymase hypothesis predicted that patients should obtain greater cardiac benefit from ARB therapy than ACE inhibitor therapy because ARB therapy would block the action of Ang II produced by chymase but clinical trials do not support this prediction. 21 Chymase inhibitors have multiple actions but there is uncertainty which, if any, of these actions are related to the reduction in Ang II levels. 22 Although chymase-mediated Ang II formation has been implicated in blood pressure regulation 17 chymase inhibition does not reduce blood pressure or plasma Ang II levels in hamsters. 23 Initial studies of Ang II levels in the cardiac interstitial fluid supported a role for non-ACE enzymatic pathways in Ang II formation in the heart 24 but subsequent studies confirmed the dominant role of ACE. 25 The report of Dell'Italia et al., 24 that microdialysate from dog cardiac ventricle has high Ang II levels that are not altered by captopril, supported a role for non-ACE enzymatic pathways in Ang II formation in the heart. However, as previously discussed, 12 there is some doubt about the reliability of the measurement of Ang peptide levels in microdialysate in these experiments, and these authors subsequently reported much lower Ang II levels in microdialysate from wild-type mouse hearts. 25 Based on their studies of microdialysate from conscious mouse hearts, Wei et al. concluded that ACE is the dominant Ang II-forming activity in the interstitial fluid of wild-type mice. 25 They also found that chronic ACE inhibition increased chymase levels 14-fold in microdialysate from mouse hearts, accompanied by an approximate 2.4fold increase in Ang I levels, but that Ang II levels were unchanged. 25 Thus, despite the 2.4-fold increase in Ang I levels, the 14-fold increase in chymase levels failed to increase Ang II levels, and the Ang II/Ang I ratio in microdialysate was reduced by more than 50%, further supporting the dominant role of ACE in Ang II formation in the cardiac interstitial fluid of these mice. In addition, Wei et al. 25 reported that the subsequent treatment of ACE inhibitortreated mice with a chymase inhibitor reduced Ang II levels in microdialysate fluid. However, this effect of chymase inhibition was inconsistent with the failure of the 14-fold increase in chymase levels to increase Ang II levels. The failure of the increased chymase levels to increase Ang II levels may have been due to chymase inhibition by the high level of protease inhibitors in cardiac interstitial fluid. 26 In conclusion, renin and ACE are the predominant pathways of Ang II formation in human plasma and heart, and in plasma and tissues of experimental animals. However, a role for other proteases and peptidases in specific tissue compartments and, in particular, pathological circumstances cannot be excluded.
